Doxorubicin conjugated with nanodiamonds and in free form commit glioblastoma cells to heterodromous fates

Nanomedicine (Lond). 2019 Feb;14(3):335-351. doi: 10.2217/nnm-2018-0330. Epub 2019 Jan 24.

Abstract

Aim: To mechanistically compare the effects of doxorubicin (DOX) and DOX conjugated with nanodiamonds (Nano-DOX) on human glioblastoma cells (GC).

Materials & methods: GC viablity, proliferation and activation of apoptosis and autophagy was assayed in response to DOX and Nano-DOX. Expression and release of HMGB1 were measured and its role in apoptosis and autophagy probed in response to DOX and Nano-DOX. Results: DOX induced apoptosis in GC while Nano-DOX induced autophagy. Inhibition of autophagy in Nano-DOX-treated GC promoted apoptosis. DOX suppressed the emission of HMGB1 while Nano-DOX stimulated HMGB1 emission which was attenuated when autophagy was repressed. Blocking of HMGB1 emission mitigated autophagy and enhanced apoptosis in Nano-DOX-treated GC. Exogenously administered HMGB1 promoted autophagy and protected against apoptosis in both Nano-DOX-treated GC and DOX-treated GC.

Conclusions: Nano-DOX is a potent autophagy activator as opposed to DOX as an apoptosis inducer. Nano-DOX initiates a mutual reinforcement loop between autophagy and HMGB1 in GC and thereby protects GC against apoptosis.

Keywords: HMGB1; apoptosis; autophagy; doxorubicin; glioblastoma cells; nanodiamonds.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Apoptosis / drug effects*
  • Autophagy / drug effects*
  • Cell Line, Tumor
  • Doxorubicin / chemistry*
  • Doxorubicin / pharmacology*
  • Glioblastoma / metabolism*
  • HMGB1 Protein / pharmacology
  • Humans
  • Nanodiamonds / chemistry*

Substances

  • HMGB1 Protein
  • Nanodiamonds
  • Doxorubicin